Business Context and Reporting Period
Company: Koninklijke Philips N.V. (Royal Philips)
Reporting Period: Second Quarter (Q2) and First Half (H1) ended June 30, 2026.
Filing Date: July 28, 2026.
Context: Philips reported solid comparable sales growth driven by all business segments. The results were significantly impacted by a one-time US tariff refund benefit. The company reiterated its full-year sales outlook while increasing Adjusted EBITA and free cash flow guidance to reflect the tariff refund.
Key Financial Metrics
| Metric (EUR millions) | Q2 2026 | Q2 2025 | H1 2026 | H1 2025 |
|---|---|---|---|---|
| Sales | 4,360 | 4,338 | 8,265 | 8,434 |
| Comparable Sales Growth | 4% | 1% | 4% | (1%) |
| Income from Operations | 609 | 400 | 851 | 554 |
| Net Income | 386 | 240 | 532 | 312 |
| Adjusted EBITA | 717 | 540 | 1,069 | 894 |
| Adjusted EBITA Margin | 16.4% | 12.4% | 12.9% | 10.6% |
| Free Cash Flow | 222 | 230 | 251 | (860) |
| Net Debt | 5,676 | 5,290 (Dec 2025) | 5,676 | 5,290 (Dec 2025) |
| Cash & Equivalents | 1,789 | 1,822 | 1,789 | 1,822 |
Note: Q2 2026 Income from Operations includes a US tariff refund benefit of EUR 186 million. Adjusted EBITA margin includes a benefit of effectively 4.2% from the refund.
Material Changes vs. Prior Period
- Revenue: Q2 comparable sales grew 4% (vs. 1% in Q2 2025), driven by growth across all segments. Personal Health led with 8% growth, followed by Diagnosis & Treatment (2%) and Connected Care (2%).
- Profitability: Income from operations increased by EUR 209 million year-over-year. This was primarily driven by the EUR 186 million US tariff refund, higher sales, and lower restructuring charges, partially offset by cost inflation and higher tariffs.
- Cash Flow: Free cash flow for H1 2026 was EUR 251 million, a significant improvement from a negative EUR 860 million in H1 2025. The prior year was negatively impacted by a EUR 1,025 million payment for Philips Respironics recall-related settlements.
- Debt: Total debt decreased to EUR 7,464 million (from EUR 8,084 million at year-end 2025) due to bond repayments.
Guidance, Outlook, and Risks
Updated Full-Year 2026 Outlook
- Comparable Sales Growth: Reiterated at 3% - 4.5%.
- Adjusted EBITA Margin: Updated to 13.5% - 14.0% (previously 12.5% - 13.0%), reflecting a ~1% benefit from the US tariff refund.
- Free Cash Flow: Updated to EUR 1.5 - 1.7 billion (previously EUR 1.3 - 1.5 billion), reflecting the tariff refund.
Management Commentary
CEO Roy Jakobs highlighted disciplined execution and healthy customer demand despite an uncertain macro environment. The company largely completed the US tariff refund process and is on track with its productivity program, which aims to deliver EUR 1.5 billion in savings by 2028.
Risks and Contingencies
- Legal Proceedings: Ongoing investigations by the US Department of Justice, SEC, and State Attorneys General regarding the Philips Respironics recall. A decision on an Enterprise Chamber investigation in the Netherlands is expected in Q3 2026.
- Macro Environment: Risks include geopolitical tensions (Ukraine, Middle East), inflation, supply chain resilience, and trade tariffs.
- Regulatory: Evolving ESG disclosure requirements and product safety regulations.
Investor Verification Checklist
- Tariff Refund Sustainability: Verify the one-time nature of the EUR 186 million US tariff refund and its impact on future margin guidance.
- Respironics Litigation: Monitor the outcome of the Enterprise Chamber hearing and ongoing US DOJ/SEC investigations for potential future liabilities.
- Productivity Program: Track progress on the EUR 1.5 billion savings target to ensure it offsets cost inflation and tariff pressures.
- Order Intake: Note the 1% decline in comparable order intake in Q2 due to timing of large orders; verify if this shifts to Q3 as management indicated.
- Dividend Execution: Confirm the impact of the mixed cash/share dividend (43.8% cash) on future cash flow and share count.